picankibart vs SHR-1139
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 p19 · full Psoriasis pipeline
picankibart
Marketed by Innovent Biologics
NCT05645627 · Phase 3 · completed
CLEAR-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in 500 Chinese adults with moderate to severe plaque psoriasis. Patients received picankibart 200 mg or placebo for the first 16 weeks. The two primary endpoints at week 16 were at least 90% improvement in PASI and a clear or almost clear sPGA score. With picankibart, 80.3% reached PASI 90 and 93.5% reached sPGA 0/1, against 2.0% and 13.1% with placebo (p<0.0001 for both), so the trial met both primary endpoints. The response rates come from the peer-reviewed paper in the Journal of the American Academy of Dermatology and the p-values from the company announcement.
Reported efficacy
Percentage of participants with a Psoriasis Area and Severity Index (PASI) 90 Response (Week 56): PASI 90 maintenance at Week 56: 89.3% (100 mg) and 90.1% (200 mg) picankibart-maintenance groups vs 37.7% and 51.7% in the corresponding randomized-withdrawal groups; P < 0.0001 for both comparisons (met)
Result source: NCT06049810
SHR-1139
Developed by Jiangsu Hengrui Pharmaceuticals
NCT07051538 · Phase 1 · completed
This early-phase study randomized 64 participants to SHR-1139 or placebo under full blinding, but it was designed to check safety and tolerability, not to test whether the drug improves psoriasis, and no results have been posted, so no conclusion about benefit can yet be drawn from it. Its registered primary outcome on ClinicalTrials.gov is "Adverse events (AEs)" (with 3 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: December 2026 · NCT07719530 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | picankibart | SHR-1139 |
|---|---|---|
| PASI 75 | —Not posted · NCT05645627 | —Not reported |
| PASI 90 | 80.3% vs 2%a+78.3 vs placeboNCT05645627 | —Not reported |
| PASI 100 | —Not posted · NCT05645627 | —Not reported |
| sPGA 0/1 | —Not posted · NCT05645627 | —Not reported |
| DLQI, change | —Not posted · NCT05645627 | —Not reported |
PASI 75
- picankibart
- —Not posted · NCT05645627
- SHR-1139
- —Not reported
PASI 90
- picankibart
- 80.3% vs 2%a+78.3 vs placeboNCT05645627
- SHR-1139
- —Not reported
PASI 100
- picankibart
- —Not posted · NCT05645627
- SHR-1139
- —Not reported
sPGA 0/1
- picankibart
- —Not posted · NCT05645627
- SHR-1139
- —Not reported
DLQI, change
- picankibart
- —Not posted · NCT05645627
- SHR-1139
- —Not reported
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SHR-1139: no structured comparison results are available for Psoriasis.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
picankibart
show 1 more result
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
picankibart
Marketed by Innovent Biologics
NCT05377580 · Phase 2 · completed
This randomized, quadruple-blind, placebo-controlled Phase 2 trial enrolled 150 patients with moderately to severely active ulcerative colitis and tested several doses of picankibart against placebo. The primary endpoint was clinical remission at Week 12. The sponsor reported remission in 20.0% of patients on 200 mg and 14.0% on 600 mg versus 2.0% on placebo (p<0.05), so the primary endpoint was met; no power calculation or planned enrolment was found in the sources checked.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Evaluate the effectiveness of IBI112 in inducing clinical remission in patients with moderately to severely active ulcerative colitis (UC) (week 12): Week 12 clinical remission (primary endpoint): picankibart 200 mg 20.0% and 600 mg 14.0% vs placebo 2.0% (p<0.05). (met)
Result source: NCT05377580
SHR-1139
Developed by Jiangsu Hengrui Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT07232576 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | picankibart | SHR-1139 |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Not reported |
| Clinical remission (maintenance) | —Not reported | —Not reported |
| Clinical response (induction) | —Not reported | —Not reported |
| Endoscopic improvement (induction) | —Not reported | —Not reported |
| Corticosteroid-free remission (maintenance) | —Not reported | —Not reported |
Clinical remission (induction)
- picankibart
- —Not reported
- SHR-1139
- —Not reported
Clinical remission (maintenance)
- picankibart
- —Not reported
- SHR-1139
- —Not reported
Clinical response (induction)
- picankibart
- —Not reported
- SHR-1139
- —Not reported
Endoscopic improvement (induction)
- picankibart
- —Not reported
- SHR-1139
- —Not reported
Corticosteroid-free remission (maintenance)
- picankibart
- —Not reported
- SHR-1139
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SHR-1139: no structured comparison results are available for Ulcerative Colitis.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: picankibart's landscape · SHR-1139's landscape